To the full analysis
Ligand Pharmaceuticals stock: growth
LGNDLigand Pharmaceuticals reported $268.09M in revenue for fiscal 2025, up 60.4% on the prior year, up 10.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
3.4%
per year from 2006 to 2025, per share 1.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 10.4% | 14.1% | 3.4% |
| Revenue per share | 6.5% | 14.3% | 1.5% |
| Earnings | no data | −7.0% | no data |
| Earnings per share | no data | −6.8% | no data |
| Free cash flow | −0.5% | 4.7% | no data |
| Free cash flow per share | −4.0% | 5.0% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $140.96M | −$31.74M | −$140.3M |
| 2007 | $12.89M | $281.69M | −$98.17M |
| 2008 | $27.32M | −$98.11M | −$21.12M |
| 2009 | $38.94M | −$1.95M | −$34.32M |
| 2010 | $23.54M | −$12.52M | −$27.14M |
| 2011 | $30.04M | $10.18M | −$1.25M |
| 2012 | $31.39M | −$527K | −$8.48M |
| 2013 | $48.97M | $11.42M | $15.75M |
| 2014 | $64.54M | $12.02M | $16.07M |
| 2015 | $71.91M | $257.31M | $30.86M |
| 2016 | $108.97M | −$1.64M | $34.68M |
| 2017 | $141.1M | $12.56M | $86.41M |
| 2018 | $251.45M | $143.32M | $182.17M |
| 2019 | $120.28M | $629.3M | −$31.89M |
| 2020 | $163.56M | −$2.99M | $50.13M |
| 2021 | $241.54M | $57.14M | $70.04M |
| 2022 | $196.25M | −$33.36M | $119.93M |
| 2023 | $131.31M | $52.15M | −$4.27M |
| 2024 | $167.13M | −$4.03M | $77.41M |
| 2025 | $268.09M | $124.45M | $48.91M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.